As some myloid leukemia subtypes are resistant to the antiproliferative actions of IFNs due to a relative deficiency of IFN signaling molecules, our results support the hypothesis that ATRA therapy followed by IFN-α administration can provide an effective treatment for AML [91,94,95]. This evidence concerns the gene IFNA1 and acute myeloid leukemia.